Diabetes

There’s no single magic bullet for enabling patient-facing care in community-based pharmacy, but there are proven strategies to make substantial progress.

Health Dialog announced Tuesday that it has received Patient Oriented Accreditation from the National Committee for Quality Assurance for its disease management programs for asthma, congestive heart failure, chronic obstructive pulmonary disease, coronary heart disease and diabetes.

The Food and Drug Administration has given full approval to Sanofi’s Admelog short-acting insulin lispro — a follow-on of Eli Lilly’s Humalog. The product received tentative approval from the FDA earlier this year, and now it is the first short-acting follow-on product to get the FDA’s stamp of approval.

With the increasing trend of self-management and the rising awareness around the diabetes disease state within developing countries, blood glucose meters can be utilized to aid in adjustment of therapeutic regimen in response to blood glucose values and to help patients adjust their dietary intake, physical activity and insulin doses to improve glycaemic control on a regular basis.

This and several other factors are covered in the latest Research and Marekts report focused on diabetes care devices.

The Centers for Disease Control and Prevention will be working with the American Pharmacists Association to build infrastructure to expand a program from the National Diabetes Prevention Program within community pharmacies.

Semma Therapeutics has announced the completion of a highly oversubscribed $114 million Series B financing. Proceeds will be used to bring the company’s lead development program of encapsulated stem cell-derived islets, through proof-of-concept in patients while continuing exploration of other regenerative medicine therapeutics.

New Research from the New York University Leonard N. Stern School of Business is highlighting the role that mobile health applications can have on outcomes among patients with diabetes. NYU Stern professor Anindya Ghose and co-authors Beibei Li of Carnegie Mellon University and Citong Guo of the Harbin Institute of Technology found that over 15 months, patients who adopted a Chinese mobile health platform saw a more than 2000% reduction in glucose levels over time, on average.